BioCryst Pharmaceuticals Inc (BCRX) Stock Analysis

BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded company in the HEALTHCARE sector. It trades at $8.34, carries a market capitalization of $2.18B. This page summarizes the public market data, fundamentals, and frequently asked questions for BCRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $8.34
• Market Cap: $2.18B
• EPS: $-1.77
• 52-Week High: $11.31
• 52-Week Low: $6.00

Market Sentiment

BioCryst Pharmaceuticals Inc currently has a Bullish sentiment score of 0.18.

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. is a cutting-edge biotechnology company headquartered in Durham, North Carolina, dedicated to pioneering oral and small molecule therapeutics for rare diseases. The company’s robust pipeline features innovative treatments aimed at addressing significant unmet medical needs, with a particular emphasis on hereditary angioedema and viral infections. BioCryst is recognized for its scientific rigor and nimble approach to drug development, making it an appealing inves...

GNG Research Analysis

GNG Research scores BioCryst Pharmaceuticals Inc (BCRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BCRX.

Frequently Asked Questions

Does BCRX pay dividends?

BioCryst Pharmaceuticals Inc (BCRX) does not currently pay a regular dividend.

What is BCRX's market cap?

BioCryst Pharmaceuticals Inc (BCRX) has a market capitalization of $2.18B with a current stock price of $8.34.